Treatment for Recurrent Hepatitis C Virus Infection After Liver Transplantation

Transplantation Proceedings

Volumn 41, Issue 3, 2009, Pages 891-894

  Balbi, E ^a   Leal, C R G ^a   Pacheco Moreira, L F ^a   Pousa, F S ^a   Covelo, M C ^a   Gonzalez, A C ^a   Oliveira, P V ^a   Agoglia, L ^a   Roma, J ^a   Carius L P ^a   Enne, M ^a  

^a HOSPITAL GERAL DE BONSUCESSO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; INTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DECOMPENSATED LIVER CIRRHOSIS; DERMATITIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MENTAL DISEASE; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT INFECTION; SCORING SYSTEM; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; BIOPSY; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 64349101083     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.02.006     Document Type: Article

References (12)

1. Liver Transplant Registry-ELTR. Registry for the European Liver Transplant Association, data analysis, 05/1968-12/2005. http://www.eltr.org
2. Féray C., Caccamo L., Casanovas T., et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 117 (1999) 619
3. Berenguer M., Ferrell L., Watson J., et al. HCV-related fibrosis progression following liver transplantation increase in recent years. J Hepatol 32 (2000) 673
4. Berenguer M., Prieto M., Rayon J.M., et al. Natural history of clinically compensated hepatitis C virus related graft cirrhosis after liver transplantation. Hepatology 32 (2000) 852
5. Berenguer M. Host and donor pre- and post-liver transplant risk factors impacting on HCV recurrence. Liver Transpl 9 (2003) S58
6. Samuel D., and Roche B. Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: difficult to manage but essential for success. J Hepatol 46 (2007) 988
7. Shergill A.K., Khalili M., Straley S., et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing LT. Am J Transplant 5 (2005) 118
8. Castells L., Vargas V., Allende H., et al. Combined treatment with pegylated interferon (alpha-2b) and RBV in the acute phase of hepatitis C virus recurrence after LT. J Hepatol 43 (2005) 53
9. Blasco A., Forns X., Carrion J.A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis recurrence after liver transplantation. Hepatology 43 (2006) 492
10. Féray C., Samuel D., Gigou M., et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 22 (1995) 1084
11. Samuel D., Bizollon T., Féray C., et al. Interferon alfa 2b plus ribavirin in patients with recurrent HCV infection after liver transplantation: a randomized study. Gastroenterology 124 (2003) 642
12. Terrault N.A., and Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 12 (2006) 1192